Cambrex Nears Completion of $100M Investment Plan One Year Early

• Cambrex, a development and manufacturing organisation (CDMO), is nearing the completion of its 5-year, $100-million-dollar investment strategy, one year ahead of schedule.

• The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network.

• The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.

Cambrex, a contract development and manufacturing organisation (CDMO), is nearing the completion of its ambitious 5-year, $100-million-dollar investment strategy with the completion of the project expected by the end of 2024.

The investment strategy, which was originally planned to span five years, is now expected to be completed one year ahead of schedule. This project has added more than 150,000 square-feet of capacity and capability expansions across 70% of Cambrex’s North American and European drug development and manufacturing network.

The investment has led to expansions in various locations, including Charles City, Iowa; High Point, North Carolina; Longmont, Colorado; Waltham, Massachusetts; Milan, Italy; and Liege, Belgium. The investment was made to align with the future needs of Cambrex’s pharmaceutical customers. It includes specialized technologies to accelerate the development of highly potent APIs and complex synthetic candidates.

The investment strategy included capacity expansions in North America and Europe, adding clinical and commercial manufacturing suites for small-volume, large-volume and highly potent API manufacturing. In addition, Cambrex expanded its capabilities in Longmont, Colorado, co-locating analytical services in the same facility as drug substance and drug product development.

Tom Loewald, Chief Executive Officer at Cambrex, commented on the progress, saying, “When we began this journey, we aligned our investment strategy to the future needs of our pharmaceutical customers. In addition to manufacturing capacity, we invested in specialized technologies to accelerate the development of highly potent APIs and complex synthetic candidates. I’m thrilled to announce that these capabilities and capacity will be available to the market well ahead of schedule, showcasing the efforts of our talented site operations and engineering teams.”